• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Impel NeuroPharma rebrands to Impel Pharmaceuticals as part of corporate transformation

April 25, 2022 By Sean Whooley

Impel Neuropharma logo updatedImpel NeuroPharma (Nasdaq:IMPL) announced today that it changed its name to Impel Pharmaceuticals as part of a corporate rebrand.

Seattle-based Impel develops proprietary Precision Olfactory Delivery (POD) technology to treat patients suffering from diseases across a range of areas in addition to the central nervous system. The company’s Trudhesa nasal spray for treating migraine in adults received FDA approval in September 2021, and the company followed the regulatory nod with the pricing of a $45 million offering a week later.

According to a news release, the new name reflects the company’s ongoing corporate and strategic transformation as it marks the one-year anniversary of becoming a publicly-traded company.

Effective at market close today (April 25, 2022), the company will trade under its new name of Impel Pharmaceuticals while retaining the same IMPL ticker.

“The first-cycle approval and launch of Trudhesa using our proprietary POD technology reinforces the promise of the device to provide potential treatment options for multiple disease areas by delivering drugs into the vascular-rich upper nasal space,” Impel Chair and CEO Adrian Adams said in the release. “Now, as we celebrate our one-year anniversary as a publicly-traded company, changing our name to Impel Pharmaceuticals cements the company’s expanded corporate mission to provide transformative therapies for people suffering from diseases beyond the central nervous system.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Neurological, Otolaryngology Ear, Nose & Throat, Pharmaceuticals Tagged With: Impel NeuroPharma Inc., Impel Pharmaceuticals

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS